Synapse - Nursing

Results (226)

Symptoms, unmet needs, and quality of life in Erdheim-Chester disease: A longitudinal registry-based analysis

Journal Article

Marathe, P. H.; Reiner, A. S.; Bossert, D.; Sigler, A. M.; Fournier, D.; Brewer, K.; Goyal, G.; Atkinson, T. M.; Mao, J. J.; Panageas, K. S.; more...
Blood Advances (2025)

Fulltext@MSK | Save

Anxiety and depression in patients with histiocytic neoplasms and their associated clinical features

Journal Article

Reiner, A. S.; Alici, Y.; Correa, D. D.; Bossert, D.; Sigler, A. M.; Fournier, D.; Brewer, K.; Goyal, G.; Atkinson, T. M.; Marathe, P.; more...
Blood Advances (2025)

Fulltext@MSK | Save

Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies

Journal Article

Shahid, S.; Prockop, S. E.; Flynn, G. C.; Mauguen, A.; White, C. O.; Bieler, J.; McAvoy, D.; Hosszu, K.; Cancio, M. I.; Jakubowski, A. A.; more...
Blood Advances (2025)

Fulltext@MSK | Save

Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease

Research Letter

Goyal, G.; Reiner, A. S.; Bossert, D.; Sigler, A. M.; Lacouture, M. E.; Rotemberg, V.; Francis, J. H.; Go, R. S.; Rampal, R. K.; Diamond, E. L.
Blood (2025)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Journal Article

Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
Blood (2025)

Fulltext@MSK | Save

Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma

Meeting Abstract

Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
Blood (2024)

Fulltext@MSK | Save

Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)

Meeting Abstract

Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
Blood (2024)

Fulltext@MSK | Save

Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)

Meeting Abstract

Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
Blood (2024)

Fulltext@MSK | Save

A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma

Meeting Abstract

Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
Blood (2024)

Fulltext@MSK | Save

Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma

Meeting Abstract

Moskowitz, A.; Ganesan, N.; Chang, T.; Davey, T.; Hancock, H.; Smith, M.; Assini, A.; Sarmasti, L.; Miller, T.; Gibaldi, A.; more...
Blood (2024)

Fulltext@MSK | Save